Edgewise Therapeutics Q4 2022 Earnings Report
Key Takeaways
Edgewise Therapeutics reported a net loss of $19.4 million, or $0.31 per share, for the fourth quarter of 2022. The company's cash, cash equivalents and marketable securities were $352 million as of December 31, 2022. They are advancing EDG-5506 clinical trials and EDG-7500 IND-enabling studies.
Advanced Phase 2 trials of EDG-5506 in Becker muscular dystrophy (BMD, CANYON) and Duchenne muscular dystrophy (DMD, LYNX).
Initiated Phase 2 exercise challenge trial of EDG-5506 in Limb girdle muscular dystrophy 2i (LGMD2I), BMD and McArdle’s Disease (DUNE).
Initiated IND-enabling studies of EDG-7500, a novel sarcomere modulator for hypertrophic cardiomyopathy (HCM); Phase 1 start expected in 2H2023.
Cash, cash equivalents and marketable securities of $352 million as of December 31, 2022.